减重24.3%！诺和诺德(NVO.US)新一代减肥药Amycretin小型试验取得积极成果

Core Viewpoint - Novo Nordisk's newly developed weight loss drug, amycretin, has shown promising results in a small study, helping patients achieve a weight loss of 24.3%, indicating its potential to become a new generation treatment in a competitive market [1][3]. Group 1: Drug Efficacy and Research - In a 36-week trial, participants using amycretin lost an average of 24.3% of their body weight, while those receiving a placebo only lost 1.1% [1][3]. - Earlier trials indicated that a weekly injection of 20 mg of amycretin resulted in a 22% weight loss, raising investor expectations for the compound [3]. - Patients taking oral amycretin tablets lost up to 13.1% of their weight within just 12 weeks [3]. Group 2: Competitive Landscape - Novo Nordisk's current best-selling product, Wegovy, has been surpassed in the key U.S. market by Eli Lilly's Zepbound, highlighting the need for amycretin to stand out [1]. - The next-generation candidate, CagriSema, has not met the company's expectations in large-scale studies, increasing the importance of amycretin's success [1]. Group 3: Development Plans - Novo Nordisk is actively advancing research projects to obtain approval for amycretin, with plans to test both oral and injectable forms of the compound [2]. - The company aims to recruit patients for later-stage trials starting early next year [2]. Group 4: Safety and Side Effects - The primary side effects of amycretin are gastrointestinal symptoms, with a temporary sensation of burning or itching reported in 5% to 29% of patients [3]. - An expert noted that the drug appears safe in trials, although there may be biases due to one-third of participants dropping out for reasons unrelated to side effects [4].